Chemotherapeutics
Abstract
The article contains sections titled:
1. |
Introduction |
2. |
Chemotherapy of Bacterial Infections |
2.1. |
Classification of Bacteria Causing Disease |
2.2. |
Emergence of New Bacterial Pathogens |
2.3. |
Antimicrobial Resistance |
2.4. |
Pathogenesis and Virulence Factors |
2.5. |
Selection of an Appropriate Antimicrobial Agent |
2.6. |
Chemoprophylaxis |
2.7. |
Chemotherapy |
2.7.1. |
Biochemical Targets for Antimicrobial Agents |
2.7.2. |
Quinolone Antibacterial Agents |
2.7.2.1. |
Structure Function |
2.7.2.2. |
Mechanism of Action |
2.7.2.3. |
Nalidixic Acid and First-Generation Quinolones |
2.7.2.4. |
Second-Generation Fluoroquinolones |
2.7.3. |
Sulfa Drugs |
2.7.3.1. |
Biological Activity and Medical Uses |
2.7.3.2. |
Mechanism of Action and Antimicrobial Resistance |
2.7.3.3. |
Structure - Function Relationships |
2.7.3.4. |
Pharmacokinetics |
2.7.3.5. |
Toxicity and Drug Interactions |
2.7.3.6. |
Combination Therapy |
2.7.3.7. |
Rapidly Absorbed Short- and Medium-Acting Sulfa Drugs |
2.7.3.8. |
Long-Acting Sulfonamides |
2.7.3.9. |
Sulfonamides for Use in the Gastrointestinal Tract |
2.7.4. |
Agents for Treating Mycobacterial Infections |
2.7.4.1. |
Antituberculosis Agents |
2.7.4.2. |
Antileprosy Agents |
2.7.5. |
Miscellaneous Nitroheterocycles Used to Treat Bacterial Infection |
3. |
Chemotherapy of Protozoan Infections |
3.1. |
Classification of Pathogenic Protozoa |
3.2. |
Flagellates |
3.2.1. |
Hemoflagellates |
3.2.1.1. |
African Trypanosomiasis |
3.2.1.1.1. |
Biology and Epidemiology |
3.2.1.1.2. |
Chemotherapy |
3.2.1.2. |
American Trypanosomiasis |
3.2.1.2.1. |
Biology and Epidemiology |
3.2.1.2.2. |
Chemotherapy |
3.2.1.3. |
Leishmaniasis |
3.2.1.3.1. |
Biology and Epidemiology |
3.2.1.3.2. |
Chemotherapy |
3.2.2. |
Intestinal and Urogenital Flagellates |
3.2.2.1. |
Trichomonas Vaginalis |
3.2.2.1.1. |
Biology and Epidemiology |
3.2.2.1.2. |
Chemotherapy |
3.2.2.2. |
Giardia Lamblia |
3.2.2.2.1. |
Biology and Epidemiology |
3.2.2.2.2. |
Chemotherapy |
3.3. |
Sporozoans |
3.3.1. |
Plasmodia |
3.3.1.1. |
Biology and Epidemiology |
3.3.1.2. |
Chemotherapy |
3.3.2. |
Babesia |
3.3.3. |
Isosporiasis |
3.3.4. |
Toxoplasmosis |
3.3.5. |
Cryptosporidium |
3.3.6. |
Pneumocystis Carinii |
3.4. |
Ciliates |
3.5. |
Amebas |
3.5.1. |
Biology and Epidemiology |
3.5.2. |
Chemotherapy |
4. |
Chemotherapy of Viral Infections |
4.1. |
Physical and Biological Characteristics |
4.2. |
Classification of Viruses |
4.3. |
Assessment of Antiviral Activity in Cell Culture |
4.4. |
Animal Models of Virus Infection |
4.5. |
Rationale for Chemotherapy of Viral Infections |
4.6. |
Chemotherapeutic Agents |
4.6.1. |
Nucleoside Analogues |
4.6.2. |
Phosphonoacetate and Phosphonoformate |
4.6.3. |
Amantadine and Rimantadine |
4.6.4. |
Enviroxime |
4.6.5. |
4′,6-Dichloroflavan |
4.6.6. |
Chalcone Ro 09 - 0410 |
4.6.7. |
Arildone and Disoxaril |
4.6.8. |
3′-Azidothymidine |
4.6.9. |
Suramin |
4.6.10. |
HPA 23 |
